OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
Brian Epling, Joseph M. Rocco, Kristin L. Boswell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11
Brian Epling, Joseph M. Rocco, Kristin L. Boswell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11
Showing 11 citing articles:
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90
Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Mandy Sze‐Man Lai, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2245086-e2245086
Open Access | Times Cited: 41
Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Mandy Sze‐Man Lai, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2245086-e2245086
Open Access | Times Cited: 41
The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19
Miklós Bege, Anikó Borbás
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 12
Miklós Bege, Anikó Borbás
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 12
Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir
Eric Y. Dai, Kannon A. Lee, Audrey B. Nathanson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 30
Eric Y. Dai, Kannon A. Lee, Audrey B. Nathanson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 30
Viral and Symptom Rebound in Untreated COVID-19 Infection
Rinki Deo, Manish C. Choudhary, Carlee Moser, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 19
Rinki Deo, Manish C. Choudhary, Carlee Moser, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 19
Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
Kévin Bihan, Lorène Lipszyc, F. Lemaı̂tre, et al.
Therapies (2023) Vol. 78, Iss. 5, pp. 531-547
Open Access | Times Cited: 10
Kévin Bihan, Lorène Lipszyc, F. Lemaı̂tre, et al.
Therapies (2023) Vol. 78, Iss. 5, pp. 531-547
Open Access | Times Cited: 10
Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action
A. Chiarelli, Hana M. Dobrovolny
Interdisciplinary Sciences Computational Life Sciences (2024) Vol. 16, Iss. 4, pp. 844-853
Closed Access | Times Cited: 3
A. Chiarelli, Hana M. Dobrovolny
Interdisciplinary Sciences Computational Life Sciences (2024) Vol. 16, Iss. 4, pp. 844-853
Closed Access | Times Cited: 3
Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
Hannah A. Blair
Drugs & Therapy Perspectives (2022) Vol. 39, Iss. 2, pp. 41-47
Open Access | Times Cited: 12
Hannah A. Blair
Drugs & Therapy Perspectives (2022) Vol. 39, Iss. 2, pp. 41-47
Open Access | Times Cited: 12
Safety Profile of Paxlovid in the Treatment of COVID-19
Bing Lv, Xin Gao, Guoqiang Zeng, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 9, pp. 666-675
Closed Access | Times Cited: 1
Bing Lv, Xin Gao, Guoqiang Zeng, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 9, pp. 666-675
Closed Access | Times Cited: 1
Effectiveness of Paxlovid - a review
Sydney Paltra, Tim Conrad
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Sydney Paltra, Tim Conrad
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
REAL-WORLD EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR ON COVID-19-ASSOCIATED HOSPITALIZATION PREVENTION: A POPULATION-BASED COHORT STUDY IN THE PROVINCE OF QUÉBEC, CANADA
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
